Exicure

Exicure Current Assets

The Current Assets of Exicure (XCUR) as of Nov 16, 2026 is 4.57 M USD. In the previous year, Current Assets was 13.15 M USD — a change of -65.28% (lower).

Current Assets

4.57 MUSD

YoY

-65.28%

Last updated:

Current Assets of Exicure is 2025 4.57 M USD. Current Assets of Exicure was 2024 13.15 M USD. It decreases by -65.28% lower compared to the previous year.

The Exicure Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
27.66 M USD
Jan 1, 2019
113.69 M USD
Jan 1, 2020
89.34 M USD
Jan 1, 2021
43.67 M USD
Jan 1, 2022
10.56 M USD
Jan 1, 2023
1.52 M USD
Jan 1, 2024
13.15 M USD
Jan 1, 2025
4.57 M USD
The Exicure Current Assets history
YEARCurrent AssetsYoY
4.57 MUSD-65.28%
13.15 MUSD+762.99%
1.52 MUSD-85.57%
10.56 MUSD-75.81%
43.67 MUSD-51.12%
89.34 MUSD-21.41%
113.69 MUSD+311.02%
27.66 MUSD+0.19%
27.61 MUSD+37.86%
20.03 MUSD+4.25%
19.21 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Exicure Stock analysis

What does Exicure do? Exicure, Inc. generates revenue through the development and commercialization of therapeutic products based on its Spherical Nucleic Acid (SNA) technology. The company focuses on immuno-oncology, genetic disorders, and other indications, with a pipeline including AST-008, XCUR-FXN, and XCUR17. AST-008 is a toll-like receptor 9 agonist designed to activate the innate immune system and induce anti-cancer responses, particularly when combined with checkpoint inhibitors. XCUR-FXN targets Friedreich’s ataxia (FA) in preclinical development, while XCUR17 is an SNA targeting IL-17RA mRNA for inflammatory disorders, Netherton syndrome, and hair loss disorders. The primary buyers of Exicure's products are pharmaceutical companies and healthcare providers seeking innovative treatments for complex conditions. The company's SNA technology enables therapeutic oligonucleotides to work across various cells and tissues, addressing unmet medical needs in immuno-oncology and genetic disorders. Commercial partnerships and licensing agreements are likely key revenue streams, though specific partners are not named in the business description. Exicure's product segments include immuno-oncology (AST-008), genetic disorders (XCUR-FXN), and inflammatory conditions (XCUR17). These segments target patients with specific diseases, such as cancer, Friedreich’s ataxia, and inflammatory disorders, where current treatments are limited. The company's focus on SNA technology differentiates its approach, aiming to unlock new therapeutic possibilities in these areas. Exicure is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Exicure stock

Current Assets of Exicure is 4.57 M USD in 2025.

Current Assets of Exicure changed from 13.15 M USD to 4.57 M USD, representing a -65.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Exicure since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Exicure historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Exicure

All Key Metrics — Exicure